British journal of pharmacology · 2026
Association of altered body composition with cardiac wasting in cancer with and without cardiotoxic therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hadzibegovic Sara, Hella Jonathan L, Porthun Jan, Lena Alessia, Krug Danara, Baluta Iulia, Wilkenshoff Ursula, Mahabadi Amir A, Totzeck Matthias, Rassaf Tienush, Anker Stefan D, Doehner Wolfram, Keller Ulrich, Bullinger Lars, Modest Dominik P, Laird Barry J A, Skipworth Richard J E, Cleland John G F, Oeing Christian, von Haehling Stephan, Landmesser Ulf, Anker Markus S
Аннотация
BACKGROUND AND PURPOSE: In advanced cancer, associations among changes in body composition, cardiac wasting and prior cardiotoxic anticancer therapy have not been investigated.
EXPERIMENTAL APPROACH: Using bioelectrical impedance analysis (BIA), body composition was measured in 206 patients with mostly advanced cancer without known cardiovascular disease or infection (stage III/IV: 84%, prior cardiotoxic anticancer therapy: 55%). Left ventricular (LV) mass was assessed by transthoracic echocardiography and grouped by presence of cardiac wasting according to previously established sex-specific thresholds for LV mass adjusted for height2 (<61 g/m2 for women, <57 g/m2 for men). BIA measurements (indexed to height2) included fat mass index (FMI), fat-free mass index (FFMI), skeletal muscle mass index (SMMI), visceral fat index (VFI), total body water index (TBWI) and extracellular water index (ECWI).
KEY RESULTS: Patients with cancer and cardiac wasting (n = 88) were younger (57±15 vs 62±13 years) and more often women (68% vs 29%) compared to those without cardiac wasting (n = 118). Patients with cardiac wasting had significantly lower FMI (-12%), FFMI (-14%), SMMI (-16%), VFI (-46%), TBWI (-13%) and ECWI (-14%). For women, FFMI was significantly associated with LV mass/height2 (r = 0.41) and VFI for men (r = 0.40). In the multivariable linear regression analysis, FFMI was the strongest significant predictor of cardiac wasting, with no significant interaction by sex or previous cardiotoxic therapy.
CONCLUSIONS AND IMPLICATIONS: Cardiac wasting in advanced cancer is associated with lower FFMI and VFI independent of prior cardiotoxic therapy.
EXPERIMENTAL APPROACH: Using bioelectrical impedance analysis (BIA), body composition was measured in 206 patients with mostly advanced cancer without known cardiovascular disease or infection (stage III/IV: 84%, prior cardiotoxic anticancer therapy: 55%). Left ventricular (LV) mass was assessed by transthoracic echocardiography and grouped by presence of cardiac wasting according to previously established sex-specific thresholds for LV mass adjusted for height2 (<61 g/m2 for women, <57 g/m2 for men). BIA measurements (indexed to height2) included fat mass index (FMI), fat-free mass index (FFMI), skeletal muscle mass index (SMMI), visceral fat index (VFI), total body water index (TBWI) and extracellular water index (ECWI).
KEY RESULTS: Patients with cancer and cardiac wasting (n = 88) were younger (57±15 vs 62±13 years) and more often women (68% vs 29%) compared to those without cardiac wasting (n = 118). Patients with cardiac wasting had significantly lower FMI (-12%), FFMI (-14%), SMMI (-16%), VFI (-46%), TBWI (-13%) and ECWI (-14%). For women, FFMI was significantly associated with LV mass/height2 (r = 0.41) and VFI for men (r = 0.40). In the multivariable linear regression analysis, FFMI was the strongest significant predictor of cardiac wasting, with no significant interaction by sex or previous cardiotoxic therapy.
CONCLUSIONS AND IMPLICATIONS: Cardiac wasting in advanced cancer is associated with lower FFMI and VFI independent of prior cardiotoxic therapy.